Personalized Medicine at FDA: The Scope & Significance of Progress in 2022

14 March 2023 Personalized Medicine Bulletin Blog
Author(s): Antoinette F. Konski

The Personalized Medicine Coalition (PMC) recently released its annual report on the progress of precision medicine as measured by precision medicine FDA approvals in 2022 (“Report”). As summarized in the Report, 2022 milestones include progress in diagnostics, therapeutics and new treatment modalities.

1.  12 new drugs identified as personalized medicines were approved in 2022, which represented about 34 percent of all newly approved drugs last year.

2.  5 new gene or cell based therapies were approved in 2022. These include treatment of rare genetic disorders with few other treatment options - beta thalassemia, hemophilia B, and cerebral adrenoleukodystrophy, refractory multiple myeloma, and certain types of non-muscle invasive bladder cancer.

3.  12 diagnostic testing systems were cleared or approved. Of the 12, three were new blood based biomarker tests for personalized cancer therapies. In addition, several of the 2022 approved indications will advance tumor-agnostic testing to guide therapeutic interventions for certain cancer patients.

4.  Tumors with KRAS mutations were once considered resistant to therapy. However, in 2022, a new therapy to treat non-small cell lung cancer harboring KRAS G12C genetic mutations was approved, now the second targeted therapy for these cancers.

5.  FDA also released two draft guidance documents that will serve to advance the developing fields of gene therapy and chimeric antigen receptor therapy. The Report indicates that the “documents promise to further enhance the efficacy with which product developers can develop submissions for this groundbreaking class of personalized treatments.”

6.  The first of a new class of drugs – T cell engagers – was approved. The drug treats a rare form of eye cancer termed HLA-A*01:01 positive uveal melanoma. T cell engagers bind to a protein found on the tumors of patients to elicit an immune response.

PMC’s report concludes that the continued development of personalized therapies continues to improve patient outcomes and make health care more efficient, but such progress must not be taken for granted, urging policymakers to continue to support policies that encourage advancement in the field.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services